1. Please check and comment entries here.
Table of Contents

    Topic review

    MLH1 Gene

    View times: 20
    Submitted by:
    (This entry belongs to Entry Collection "MedlinePlus ")

    Definition

    mutL homolog 1

    1. Introduction

    The MLH1 gene provides instructions for making a protein that plays an essential role in repairing DNA. This protein helps fix errors that are made when DNA is copied (DNA replication) in preparation for cell division. The MLH1 protein joins with another protein called PMS2 (produced from the PMS2 gene), to form a two-protein complex called a dimer. This complex coordinates the activities of other proteins that repair errors made during DNA replication. The repairs are made by removing a section of DNA that contains errors and replacing the section with a corrected DNA sequence. The MLH1 gene is one of a set of genes known as the mismatch repair (MMR) genes. The MLH1 protein can also form a dimer with the MLH3 or PMS1 protein (each produced from different genes), but the function of these dimers is not well understood.

    2. Health Conditions Related to Genetic Changes

    2.1. Constitutional mismatch repair deficiency syndrome

    About 10 mutations in the MLH1 gene have been associated with condition called constitutional mismatch repair deficiency (CMMRD) syndrome. Individuals with this condition are at increased risk of developing cancers of the colon (large intestine) and rectum (collectively referred to as colorectal cancer), brain, and blood (leukemia or lymphoma). These cancers usually first occur in childhood, with the vast majority of cancers in CMMRD syndrome diagnosed in people under the age of 18. Many people with CMMRD syndrome also develop changes in skin coloring (pigmentation), similar to those that occur in a condition called neurofibromatosis type 1.

    Individuals with CMMRD syndrome inherit two MLH1 gene mutations, one from each parent, while people with Lynch syndrome (described below) have a mutation in one copy of the MLH1 gene.

    MLH1 gene mutations result in near or complete loss of MLH1 protein production. A shortage of this protein eliminates mismatch repair activity and prevents the proper repair of DNA replication errors. These errors accumulate as the abnormal cells continue to divide. The errors disrupt other genes involved in important cellular processes, such as controlling cell growth and division (proliferation). If cell growth is uncontrolled, it can lead to childhood cancer in people with CMMRD syndrome.

    It is thought that the features of neurofibromatosis type 1 in people with CMMRD syndrome are due to genetic changes in the NF1 gene that result from loss of mismatch repair. These changes are present only in certain cells (somatic mutations), whereas NF1 gene mutations that are present in all cells of the body cause neurofibromatosis type 1.

    2.2. Lynch syndrome

    About 40 percent of all cases of Lynch syndrome with an identified gene mutation are associated with inherited mutations in the MLH1 gene. Several hundred MLH1 gene mutations have been found in people with this condition. Lynch syndrome increases the risk of many types of cancer, particularly colorectal cancer. People with Lynch syndrome also have an increased risk of cancers of the endometrium (lining of the uterus), ovaries, stomach, small intestine, gallbladder ducts, upper urinary tract, and brain. By age 75, the risk of developing one of these cancers is 80 percent for women and 70 percent for men with an MLH1 gene mutation.

    MLH1 gene mutations involved in this condition prevent the production of the MLH1 protein from one copy of the gene or lead to an altered version of this protein that does not function properly. A decrease in functional MLH1 protein leads to an increase in unrepaired DNA errors during cell division. The errors accumulate as the cells continue to divide, which may cause the cells to function abnormally, increasing the risk of tumor formation in the colon or another part of the body.

    Because there is some functional MLH1 protein produced from the normal copy of the gene, mismatch repair activity in Lynch syndrome is reduced but not absent, as it is in CMMRD syndrome (described above). This difference in DNA repair activity levels likely explains why cancers in Lynch syndrome generally develop in adulthood while those in CMMRD syndrome often affect children.

    Some mutations in the MLH1 gene cause a variant of Lynch syndrome called Muir-Torre syndrome. In addition to colorectal cancer, people with this condition have an increased risk of developing several uncommon skin tumors. These rare skin tumors include sebaceous adenomas and carcinomas, which occur in glands that produce an oily substance called sebum (sebaceous glands). Multiple rapidly growing tumors called keratoacanthomas may also occur, usually on sun-exposed areas of skin.

    2.3. Ovarian cancer

    Inherited changes in the MLH1 gene increase the risk of developing ovarian cancer, as well as other types of cancer, as part of Lynch syndrome (described above). Women with Lynch syndrome have an 8 to 10 percent chance of developing ovarian cancer, as compared with 1.6 percent in the general population.

    3. Other Names for This Gene

    • hMLH1

    • MLH1_HUMAN

    • mutL (E. coli) homolog 1 (colon cancer, nonpolyposis type 2)

    • mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)

    • MutL protein homolog 1

    This entry is adapted from https://medlineplus.gov/genetics/gene/mlh1

    References

    1. Andersen SD, Liberti SE, Lützen A, Drost M, Bernstein I, Nilbert M, Dominguez M, Nyström M, Hansen TV, Christoffersen JW, Jäger AC, de Wind N, Nielsen FC,Tørring PM, Rasmussen LJ. Functional characterization of MLH1 missense variantsidentified in Lynch syndrome patients. Hum Mutat. 2012 Dec;33(12):1647-55. doi:10.1002/humu.22153.
    2. Bandipalliam P. Syndrome of early onset colon cancers, hematologicmalignancies & features of neurofibromatosis in HNPCC families with homozygousmismatch repair gene mutations. Fam Cancer. 2005;4(4):323-33. Review.
    3. Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP,Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, BalaguerF, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen CappelWH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A,Lopez-Köstner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, Büttner R, Görgens H,Holinski-Feder E, Morak M, Holzapfel S, Hüneburg R, Knebel Doeberitz MV, LoefflerM, Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, PylvänäinenK, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, LeMarchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C,Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M,Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, PineroTA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslein G, Mecklin JP, Nielsen M, Møller P. Cancer risks by gene, age, and gender in 6350 carriersof pathogenic mismatch repair variants: findings from the Prospective LynchSyndrome Database. Genet Med. 2020 Jan;22(1):15-25. doi:10.1038/s41436-019-0596-9.Sep;22(9):1569.
    4. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, Antill YC,Thibodeau SN, Casey G, Gallinger S, Marchand LL, Newcomb PA, Haile RW, Young GP, James PA, Giles GG, Gunawardena SR, Leggett BA, Gattas M, Boussioutas A, AhnenDJ, Baron JA, Parry S, Goldblatt J, Young JP, Hopper JL, Jenkins MA. Cancer risksfor MLH1 and MSH2 mutation carriers. Hum Mutat. 2013 Mar;34(3):490-7. doi:10.1002/humu.22262.
    5. Kohlmann W, Gruber SB. Lynch Syndrome. 2004 Feb 5 [updated 2018 Apr 12]. In:Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A,editors. GeneReviews® [Internet]. Seattle (WA): University of Washington,Seattle; 1993-2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/
    6. Leclerc J, Flament C, Lovecchio T, Delattre L, Ait Yahya E, Baert-Desurmont S,Burnichon N, Bronner M, Cabaret O, Lejeune S, Guimbaud R, Morin G, Mauillon J,Jonveaux P, Laurent-Puig P, Frébourg T, Porchet N, Buisine MP. Diversity ofgenetic events associated with MLH1 promoter methylation in Lynch syndromefamilies with heritable constitutional epimutation. Genet Med. 2018Dec;20(12):1589-1599. doi: 10.1038/gim.2018.47.
    7. Mitchell RJ, Farrington SM, Dunlop MG, Campbell H. Mismatch repair genes hMLH1and hMSH2 and colorectal cancer: a HuGE review. Am J Epidemiol. 2002 Nov15;156(10):885-902. Review.
    8. Morak M, Ibisler A, Keller G, Jessen E, Laner A, Gonzales-Fassrainer D, LocherM, Massdorf T, Nissen AM, Benet-Pagès A, Holinski-Feder E. Comprehensive analysisof the MLH1 promoter region in 480 patients with colorectal cancer and 1150controls reveals new variants including one with a heritable constitutional MLH1 epimutation. J Med Genet. 2018 Apr;55(4):240-248. doi:10.1136/jmedgenet-2017-104744.
    9. Moufid FZ, Bouguenouch L, El Bouchikhi I, Chbani L, Iraqui Houssaini M, Sekal M, Belhassan K, Bennani B, Ouldim K. The First Molecular Screening of MLH1 andMSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively HighMutational Prevalence. Genet Test Mol Biomarkers. 2018 Aug;22(8):492-497. doi:10.1089/gtmb.2018.0067.
    10. Pande M, Wei C, Chen J, Amos CI, Lynch PM, Lu KH, Lucio LA, Boyd-Rogers SG,Bannon SA, Mork ME, Frazier ML. Cancer spectrum in DNA mismatch repair genemutation carriers: results from a hospital based Lynch syndrome registry. FamCancer. 2012 Sep;11(3):441-7. doi: 10.1007/s10689-012-9534-6.
    11. Peltomäki P. Lynch syndrome genes. Fam Cancer. 2005;4(3):227-32. Review.
    12. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usualsuspects. Gynecol Oncol. 2012 Feb;124(2):347-53. doi:10.1016/j.ygyno.2011.12.415. Review.
    13. Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lönnqvist KE,Holinski-Feder E, Sutter C, McKinnon W, Duraisamy S, Gerdes AM, Peltomäki P,Kohonen-Ccorish M, Mangold E, Macrae F, Greenblatt M, de la Chapelle A, NyströmM. Functional significance and clinical phenotype of nontruncating mismatchrepair variants of MLH1. Gastroenterology. 2005 Aug;129(2):537-49.
    14. South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A. Thefrequency of Muir-Torre syndrome among Lynch syndrome families. J Natl CancerInst. 2008 Feb 20;100(4):277-81. doi: 10.1093/jnci/djm291.
    15. Tamura K, Kaneda M, Futagawa M, Takeshita M, Kim S, Nakama M, Kawashita N,Tatsumi-Miyajima J. Correction to: Genetic and genomic basis of the mismatchrepair system involved in Lynch syndrome. Int J Clin Oncol. 2019 Sep;24(9):1012. doi: 10.1007/s10147-019-01515-w.
    More

    Keywords